Form D · Pharmaceuticals
EnBiotix, Inc.
Boston, MA · CIK 0001789774
Offering snapshot reported Apr 5, 2022 · SEC filing
- Reported sold
- $3.47M Offering amount: $5M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 21, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 5, 2022 | Initial | $3,465,000 | No comparison | 11 | SEC filing |
| Sep 30, 2019 | Initial | $3,148,176 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-440344
Source: Form D, filed Apr 5, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dennis Auisello | Director |
| Dennis Ausiello | Director |
| Roberto Guttmann | Director |
| Daniel Hartman | Director |
| Jeffrey D. Wager | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
197 W Springfield Street
Boston, MA, 02118
Boston, MA, 02118